PubMed
Stable gastric pentadecapeptide BPC 157: Novel therapy in gastrointestinal tract
Sikiric et al., 2018
Wolverine Stack · BPC-157 + TB-500
Wolverine is a community name for a pre-blended recovery vial that combines BPC-157 and TB-500 (thymosin β4 fragment) into one tracked compound. PeptIQ lists it as an educational blend entry so supplier-labeled dual vials can be logged as a single injection while component research still maps to BPC-157 and TB-500. Not an FDA-approved fixed combination — verify the vial label and treat component evidence separately.
Overall check-ins
Trackers & reports
Overview
Wolverine is a community name for a pre-blended recovery vial that combines BPC-157 and TB-500 (thymosin β4 fragment) into one tracked compound. PeptIQ lists it as an educational blend entry so supplier-labeled dual vials can be logged as a single injection while component research still maps to BPC-157 and TB-500. Not an FDA-approved fixed combination — verify the vial label and treat component evidence separately.
Community
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 59% · Mixed 28% · Unfavorable overall 13%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 0.2–0.4 mg · Most common: 0.2–0.4 mg
Reports span 0.025–2 mg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 54% said they felt similar to their last entry, 33% more positive, and 19% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 19 days · Based on 212 repeat reporters
Community charts use modeled aggregates when live Supabase snapshots are unavailable.
Research
PubMed
Sikiric et al., 2018
PubMed
Goldstein et al., 2010
Tools
More ways to learn about Wolverine Blend from observational PeptIQ data.
Compare with
Related peptides
Help
This page summarizes 965 anonymized self-reports from PeptIQ users who track Wolverine Blend, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
2 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
This wiki does not assess safety or recommend use. Wolverine Blend is listed as Research Only. Consult a licensed clinician for personal medical decisions.
Research, primarily in animal models, suggests Wolverine Blend may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.
SourceWolverine Blend is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified Wolverine Blend as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.
SourceThe safety and effectiveness of Wolverine Blend have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.
SourceWhile there are over 200 published studies on Wolverine Blend, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.
Source